5 results on '"Esophageal Cancer Consortium"'
Search Results
2. Treatment Outcomes of Esophageal Cancer
- Author
-
Westat, African Esophageal Cancer Consortium (AfrECC), National Cancer Institute (NCI), and Celgene Corporation
- Published
- 2023
3. Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
- Author
-
Buckle, Geoffrey C, Mrema, Alita, Mwachiro, Michael, Ringo, Yona, Selekwa, Msiba, Mulima, Gift, Some, Fatma F, Mmbaga, Blandina T, Mody, Gita N, Zhang, Li, Paciorek, Alan, Akoko, Larry, Ayuo, Paul, Burgert, Stephen, Bukusi, Elizabeth, Charles, Anthony, Chepkemoi, Winnie, Chesumbai, Gladys, Kaimila, Bongani, Kenseko, Aida, Kibwana, Kitembo Salum, Koech, David, Macharia, Caren, Moirana, Ezekiel N, Mushi, Beatrice Paul, Mremi, Alex, Mwaiselage, Julius, Mwanga, Ally, Ndumbalo, Jerry, Nvakunga, Gissela, Ngoma, Mamsau, Oduor, Margaret, Oloo, Mark, Opakas, Jesse, Parker, Robert, Seno, Saruni, Salima, Ande, Servent, Furaha, Wandera, Andrew, Westmoreland, Kate D, White, Russell E, Williams, Brittney, Mmbaga, Elia J, Van Loon, Katherine, and of the African Esophageal Cancer Consortium (AfrECC)
- Subjects
Quality of life ,Adult ,Male ,Cancer Research ,Comparative Effectiveness Research ,Survival ,Esophageal Neoplasms ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,Esophageal cancer ,effectiveness ,Eastern ,Study Protocol ,Clinical Research ,Esophageal squamous cell carcinoma ,parasitic diseases ,Genetics ,Humans ,Oncology & Carcinogenesis ,Longitudinal Studies ,Prospective Studies ,RC254-282 ,Comparative ,Cancer ,Palliative Care ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Evaluation of treatments and therapeutic interventions ,Health Services ,Africa, Eastern ,of the African Esophageal Cancer Consortium ,Comparative effectiveness ,Observational Studies as Topic ,Good Health and Well Being ,Treatment Outcome ,Oncology ,6.1 Pharmaceuticals ,Africa ,Public Health and Health Services ,Health Resources ,Eastern Africa ,Female ,Digestive Diseases - Abstract
Background Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radiation therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined. Methods This prospective, observational, multi-center, open cohort study aims to describe the therapeutic landscape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Tenwek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach. Discussion This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research. Trial registration This study was retrospectively registered with the ClinicalTrials.gov database on December 15, 2021, NCT05177393.
- Published
- 2022
4. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization.
- Author
-
Ong, Jue-Sheng, Dixon-Suen, Suzanne C., Han, Xikun, An, Jiyuan, Esophageal Cancer Consortium, Fitzgerald, Rebecca, Buas, Matt, Gammon, Marilie D., Corley, Douglas A., Shaheen, Nicholas J., Hardie, Laura J., Bird, Nigel C., Reid, Brian J., Chow, Wong-Ho, Risch, Harvey A., Ye, Weimin, Liu, Geoffrey, Romero, Yvonne, Bernstein, Leslie, and Wu, Anna H.
- Subjects
CANCER susceptibility ,VITAMIN D ,BASAL cell carcinoma ,OVARIAN cancer - Abstract
Previous Mendelian randomization (MR) studies on 25-hydroxyvitamin D (25(OH)D) and cancer have typically adopted a handful of variants and found no relationship between 25(OH)D and cancer; however, issues of horizontal pleiotropy cannot be reliably addressed. Using a larger set of variants associated with 25(OH)D (74 SNPs, up from 6 previously), we perform a unified MR analysis to re-evaluate the relationship between 25(OH)D and ten cancers. Our findings are broadly consistent with previous MR studies indicating no relationship, apart from ovarian cancers (OR 0.89; 95% C.I: 0.82 to 0.96 per 1 SD change in 25(OH)D concentration) and basal cell carcinoma (OR 1.16; 95% C.I.: 1.04 to 1.28). However, after adjustment for pigmentation related variables in a multivariable MR framework, the BCC findings were attenuated. Here we report that lower 25(OH)D is unlikely to be a causal risk factor for most cancers, with our study providing more precise confidence intervals than previously possible. Studies of the genetic association between vitamin D and cancer risk have typically been underpowered. Here the authors analyse this using Mendelian Randomisation with more than 70 vitamin D variants obtained from the UK Biobank and large-scale data from various consortia, confirming null associations between vitamin D and most cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
- Author
-
Geoffrey C. Buckle, Alita Mrema, Michael Mwachiro, Yona Ringo, Msiba Selekwa, Gift Mulima, Fatma F. Some, Blandina T. Mmbaga, Gita N. Mody, Li Zhang, Alan Paciorek, Larry Akoko, Paul Ayuo, Stephen Burgert, Elizabeth Bukusi, Anthony Charles, Winnie Chepkemoi, Gladys Chesumbai, Bongani Kaimila, Aida Kenseko, Kitembo Salum Kibwana, David Koech, Caren Macharia, Ezekiel N. Moirana, Beatrice Paul Mushi, Alex Mremi, Julius Mwaiselage, Ally Mwanga, Jerry Ndumbalo, Gissela Nvakunga, Mamsau Ngoma, Margaret Oduor, Mark Oloo, Jesse Opakas, Robert Parker, Saruni Seno, Ande Salima, Furaha Servent, Andrew Wandera, Kate D. Westmoreland, Russell E. White, Brittney Williams, Elia J. Mmbaga, Katherine Van Loon, and of the African Esophageal Cancer Consortium (AfrECC)
- Subjects
Esophageal squamous cell carcinoma ,Esophageal cancer ,Survival ,Quality of life ,Comparative effectiveness ,Africa ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radiation therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined. Methods This prospective, observational, multi-center, open cohort study aims to describe the therapeutic landscape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Tenwek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach. Discussion This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research. Trial registration This study was retrospectively registered with the ClinicalTrials.gov database on December 15, 2021, NCT05177393 .
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.